Literature DB >> 21697646

Growth hormone deficiency in the transition period: body composition and gonad function.

G Balercia1, L Giovannini, F Paggi, M Spaziani, N Tahani, M Boscaro, A Lenzi, A Radicioni.   

Abstract

Recombinant GH therapy is normally administered to GH-deficient children in order to achieve a satisfactory height - the main target during childhood and adolescence. However, the role of GH does not end once final height has been reached, but continues during the so-called transition period. In this phase of life, the body undergoes several changes, both physical and psychological, that culminate in adulthood. During this period, GH has a part in numerous metabolic functions. These include the lipid profile, where it increases HDL and reduces LDL, with the global effect of cardiovascular protection. It also has important effects on body composition (improved muscle strength and lean body mass and reduced body fat), the achievement of proper peak bone density, and gonad maturation. Retesting during the transition period, involving measurement of IGF-I plus a provocative test (insulin tolerance test or GHRH + arginine test), is thus necessary to establish any persistent GH deficiency requiring additional replacement therapy. The close cooperation of the medical professionals involved in the patient's transition from a pediatric to an adult endocrinologist is essential. The aim of this review is to point out the main aspects of GH treatment on body composition, metabolic and gonad functions in the transition period.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21697646     DOI: 10.3275/7804

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  70 in total

Review 1.  The insulin-like growth factor (IGF) system and gonadotropin regulation: actions and interactions.

Authors:  B R Lackey; S L Gray; D M Henricks
Journal:  Cytokine Growth Factor Rev       Date:  1999 Sep-Dec       Impact factor: 7.638

2.  Effects of recombinant growth hormone (GH) treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency.

Authors:  A Sartorio; S Ortolani; A Conti; R Cherubini; E Galbiati; G Faglia
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

3.  A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse).

Authors:  Y Zhou; B C Xu; H G Maheshwari; L He; M Reed; M Lozykowski; S Okada; L Cataldo; K Coschigamo; T E Wagner; G Baumann; J J Kopchick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 4.  Distinct and overlapping functions of insulin and IGF-I receptors.

Authors:  J Nakae; Y Kido; D Accili
Journal:  Endocr Rev       Date:  2001-12       Impact factor: 19.871

Review 5.  Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.

Authors:  E Ghigo; G Aimaretti; E Arvat; F Camanni
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

6.  Impaired sperm characteristics in postpubertal growth-hormone-deficient dwarf (dw/dw) rats.

Authors:  C G Gravance; B H Breier; M H Vickers; P J Casey
Journal:  Anim Reprod Sci       Date:  1997-09       Impact factor: 2.145

7.  Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.

Authors:  B M Biller; G Sesmilo; H B Baum; D Hayden; D Schoenfeld; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

8.  Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth.

Authors:  P V Carroll; W M Drake; K T Maher; K Metcalfe; N J Shaw; D B Dunger; T D Cheetham; C Camacho-Hübner; M O Savage; J P Monson
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

9.  Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency.

Authors:  G S Conway; M Szarras-Czapnik; K Racz; A Keller; P Chanson; M Tauber; M Zacharin
Journal:  Eur J Endocrinol       Date:  2009-03-26       Impact factor: 6.664

10.  Testicular function in boys previously treated with recombinant-human growth hormone for non-growth hormone-deficient short stature.

Authors:  A F Radicioni; E Paris; E De Marco; A Anzuini; L Gandini; A Lenzi
Journal:  J Endocrinol Invest       Date:  2007-12       Impact factor: 4.256

View more
  5 in total

1.  Synergistic effect of obesity and lipid ingestion in suppressing the growth hormone response to exercise in children.

Authors:  Stacy R Oliver; Sunita R Hingorani; Jaime S Rosa; Frank P Zaldivar; Pietro R Galassetti
Journal:  J Appl Physiol (1985)       Date:  2012-04-19

2.  Low bone mineral density in a growth hormone deficient (GHD) adolescent.

Authors:  Anna Capozzi; Silvia Della Casa; Barbara Altieri; Alfredo Pontecorvi
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

3.  A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial.

Authors:  Victoria Borrás Pérez; Juan Pedro López-Siguero; Gabriela Martínez; Raquel Corripio; Juan Manuel Fernández; Jose Ignacio Labarta; Marta Ferrer; Nuria Cabrinety; Pablo Prieto; Marta Ramón-Krauel; Jordi Bosch; Rafael Espino; Margarida Palla Garcia; Francisco Jose Rebollo
Journal:  Adv Ther       Date:  2015-02-11       Impact factor: 3.845

4.  Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome.

Authors:  Stephany H Donze; Layla Damen; Janiëlle A E M van Alfen-van der Velden; Gianni Bocca; Martijn J J Finken; Gera J G Hoorweg-Nijman; Petr E Jira; Mariëtte van Leeuwen; Anita C S Hokken-Koelega
Journal:  Clin Endocrinol (Oxf)       Date:  2019-04-30       Impact factor: 3.478

Review 5.  Clinical, Diagnostic, and Therapeutic Aspects of Growth Hormone Deficiency During the Transition Period: Review of the Literature.

Authors:  Matteo Spaziani; Chiara Tarantino; Natascia Tahani; Daniele Gianfrilli; Emilia Sbardella; Andrea M Isidori; Andrea Lenzi; Antonio F Radicioni
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-24       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.